2-氰基乙酰苯胺 | 621-03-4

• 物质功能分类: 化学试剂 - 有机试剂 - 氰酸酯/异氰酸酯
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氰基乙酰苯胺
• 中文别名: 2-氰基-N-苯基乙酰胺；N-苯基-2-氰乙酰胺
• 英文名称: cyanoacetanilide
• 英文别名: cyano-acetic acid anilide；2-cyano-N-phenylacetamide
• CAS: 621-03-4
• 化学式: C₉H₈N₂O
• mdl: MFCD00019840
• 分子量: 160.175
• InChiKey: XCTQPMCULSZKLT-UHFFFAOYSA-N

物化性质

• 熔点：
  198-202 °C
• 沸点：
  286.07°C (rough estimate)
• 密度：
  1.1846 (rough estimate)
• 溶解度：
  0.00 M
• 稳定性/保质期：
  常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S24/25
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090
• 危险性防范说明：
  P280
• 危险性描述：
  H302+H312+H332
• 储存条件：
  密封存储，应存放在阴凉干燥的仓库中。

SDS

Name:	2-Cyanoacetanilide 98% Material Safety Data Sheet
Synonym:	Acetamide, 2-Cyano-N-Phenyl-
CAS:	621-03-4

Section 1 - Chemical Product MSDS Name:2-Cyanoacetanilide 98% Material Safety Data Sheet
Synonym:Acetamide, 2-Cyano-N-Phenyl-

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
621-03-4	Acetamide, 2-Cyano-N-Phenyl-	98	210-666-6

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 621-03-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 201.00 - 203.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8N2O
Molecular Weight: 160.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 621-03-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Acetamide, 2-Cyano-N-Phenyl- - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 621-03-4: No information available.
Canada
CAS# 621-03-4 is listed on Canada's DSL List.
CAS# 621-03-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 621-03-4 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	3,3,3-trifluoro-N-phenylpropanamide	351-12-2	C9H8F3NO	203.164
  2-溴-N-苯乙酰胺	N-(phenyl)bromoacetamide	5326-87-4	C8H8BrNO	214.062
  2-氯乙酰苯胺	N-chloroacetyl-aniline	587-65-5	C8H8ClNO	169.611

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	2-cyano-propionic acid anilide	76646-62-3	C10H10N2O	174.202
  4’-氯-2-环乙酰苯胺	N-(4-chlorophenyl)-2-cyanoacetamide	17722-17-7	C9H7ClN2O	194.62
  ——	3-amino-propionanilide	57528-64-0	C9H12N2O	164.207
  2-氨基-2-氰基-N-苯乙酰胺	2-Amino-2-cyano-N-phenylacetamide	64145-17-1	C9H9N3O	175.19
  ——	Brom-cyan-acetanilid	90484-32-5	C9H7BrN2O	239.071
  2-(硫代氨基甲酰)-乙酰苯胺	3-amino-N-phenyl-3-thioxopropanamide	59749-96-1	C9H10N2OS	194.257
  氰基乙酰对三氟甲基苯胺	2-cyano-N-(4-trifluoromethylphenyl)acetamide	24522-30-3	C10H7F3N2O	228.174
  ——	(2E)-2-Cyano-3-hydroxy-N-phenyl-2-propenamide	113604-08-3	C10H8N2O2	188.18
  乙酰胺,2-氰基-2-重氮基-N-苯基-	N-phenyl-2-diazo-2-cyanoacetamide	117015-33-5	C9H6N4O	186.173
  ——	N-hydroxy-2-oxo-2-(phenylamino)acetimidoyl cyanide	3849-19-2	C9H7N3O2	189.173

反应信息

• 作为反应物：
  描述：

  2-氰基乙酰苯胺 在 水 、 sodium nitrite 作用下， 以 1,4-二氧六环 为溶剂， 以77%的产率得到N-hydroxy-2-oxo-2-(phenylamino)acetimidoyl cyanide
  参考文献：
  名称：

  利用2-氰基-N-芳基乙酰胺作为抗菌剂的新型杂环的对接合成研究。

  摘要：

  2-氰基-N-芳基乙酰胺试剂用于直接合成各种有趣的含氮杂环，如亚氨基香豆素，噻唑，二氢吡啶和咪唑或苯并咪唑。描述了分子对接研究，以显示活性最高的化合物为抗微生物剂。而且，已经对这些化合物针对某些革兰氏细菌菌株和真菌菌株的抗微生物活性进行了生物学测试。

  DOI：

  10.21608/ejchem.2020.21812.2294
• 作为产物：
  描述：

  氰乙酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以46%的产率得到2-氰基乙酰苯胺
  参考文献：
  名称：

  Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists

  摘要：

  The C-X-C motif ligand 8 and C-X-C chemokine receptor 2 (CXCL8-CXCR2) axis is involved in pathogenesis of various diseases including inflammation and cancers. Various CXCR2 antagonists are under development for several diseases. Our previous high-throughput cell-based assay specific for CXCR2 has identified a pyrimidine-based compound CX797 acting on CXCR2 down-stream signaling. A lead optimization campaign through scaffold-hopping strategy led to a series of 2-thioureidothiophene-3-carboxylates (TUTP) as novel CXCR2 antagonists. Structure-activity relationship study of TUTPs led to the identification of compound 52 that significantly inhibited CXCR2-mediated beta-arrestin recruitment signaling (IC50 = 1.1 +/- 0.01 mu M) with negligible effect on CXCL8-mediated cAMP signaling and calcium flux. Similar to the known CXCR2 antagonist SB265610, compound 52 inhibited CXCL8-CXCR2 induced phosphorylation of ERK1/2. TUTP compounds also inhibited CXCL8-mediated cell migration and showed synergy with doxorubicin in ovarian cancer cells, thereby supporting TUTPs as promising compounds for cancer treatment. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112387
• 作为试剂：
  描述：

  哌啶 、 1-(4-甲氧基-苯基)-3-苯基-propyn酮 在 2-氰基乙酰苯胺 作用下， 以 乙醇 为溶剂， 反应 72.0h， 生成 (E)-1-(4-methoxyphenyl)-3-phenyl-3-piperidin-1-ylprop-2-en-1-one 、 3-phenylformamido-6-(p-anisyl)-4-phenyl-2H-pyran-2-one
  参考文献：
  名称：

  Youssef, A. S. A.; Kandeel, K. A.; Madkour, Hassan, M. F., Journal of the Indian Chemical Society, 1995, vol. 72, # 2, p. 103 - 106

  摘要：

  DOI：

文献信息

• Water/Alkali-Catalyzed Reactions of Azides with 2-Cyanothioacetamides. Eco-Friendly Synthesis of Monocyclic and Bicyclic 1,2,3-Thiadiazole-4-carbimidamides and 5-Amino-1,2,3-triazole-4-carbothioamides
  作者：Valeriy O. Filimonov、Lidia N. Dianova、Tetyana V. Beryozkina、Dmitrii Mazur、Nikolai A. Beliaev、Natalia N. Volkova、Vladimir G. Ilkin、Wim Dehaen、Albert T. Lebedev、Vasiliy A. Bakulev

  DOI：10.1021/acs.joc.9b01599

  日期：2019.11.1

  extended to the one-pot reaction of sulfonyl chlorides and 6-chloropyrimidines 2'o with sodium azide, leading to final products in higher yields, that is, avoiding the isolation of unsafe sulfonyl azides. The method was furthermore applied to the reaction of N,N'-bis-(2-cyanothiocarbonyl)pyrazine 1h with sulfonyl azides to afford bicyclic 1,2,3-thiadiazoles 8 and 1,2,3-triazoles 9 connected via a 1,1'-piperazinyl

  研究了硫酰胺与叠氮化物在水中的反应。可靠地表明，2-氰基硫代乙酰胺1与各种类型的叠氮化物2在碱存在下的水中反应是一种高效，通用，一步一步，原子经济且生态友好的合成1的方法， 2,3-噻二唑-4-碳二酰亚胺5和1,2,3-三唑-4-碳硫酰胺4。该方法可以扩展到磺酰氯和6-氯嘧啶2'o与叠氮化钠的一锅反应，导致最终产品的收率更高，即避免了分离不安全的磺酰叠氮化物。该方法进一步应用于N，N′-双-（2-氰基硫代羰基羰基）吡嗪1h与磺酰基叠氮化物的反应，得到通过1连接的双环1,2,3-噻二唑8和1,2,3-三唑9。 ，1'-哌嗪基接头。
• Synthesis and DNase I inhibitory properties of some 4‐thiazolidinone derivatives
  作者：Ana Kolarević、Budimir S. Ilić、Gordana Kocić、Zdravko Džambaski、Andrija Šmelcerović、Bojan P. Bondžić

  DOI：10.1002/jcb.27339

  日期：2019.1

  residues Glu 39 and Asp 168. The three most active compounds against both commercial and rat liver DNase I (31, 38, and 41) exhibited favorable physico-chemical, pharmacokinetic, and toxicological properties. These observations could be utilized to guide the rational design and optimization of novel thiazolidinone inhibitors. Thiazolidinones as novel DNase I inhibitors could have potential therapeutic

  合成了十二种新的噻唑烷酮，并与41种先前合成的噻唑烷酮一起在体外评估了对脱氧核糖核酸酶I（DNase I）的抑制活性。十种化合物抑制商业牛胰腺DNase I的IC50低于200μM，并显示出比作为阳性对照的结晶紫（IC50 = 365.90±47.33μM）更有效的DNase I抑制剂。此外，三种化合物对大鼠肝脏匀浆中的DNase I具有活性，IC50低于200μM。（3-甲基-1,4-二氧噻唑啉-2-亚甲基）-N-（2-苯基乙基）乙酰胺（41）对商业和大鼠肝脏DNase I的DNase I抑制作用最强，IC50值为115.96±11.70，分别为151.36±15.85μM。Site Finder和分子对接定义了噻唑烷酮与DNase I最重要的催化残基的相互作用，包括与残基His 134和His 252的H-受体相互作用和/或与残基Glu 39和Asp 168的H-供体相互作用。对抗商业和大鼠肝脏DNase
• Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma
  作者：Xuewu Liang、Chenxia Sun、Chunpu Li、Haolan Yu、Xiaohui Wei、Xuyi Liu、Wei Bao、Yuqiang Shi、Xiaochen Sun、Mirzadavlat Khamrakulov、Chenghua Yang、Hong Liu

  DOI：10.1021/acs.jmedchem.1c00466

  日期：2021.7.8

  lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors is of great value and significance in the treatment of neoplastic disorders and inflammatory and autoimmune diseases. However, there is a lack of effective MALT1 inhibitors in clinic. Herein, a novel class of potent 5-oxo-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline-based MALT1 inhibitors and their covalent derivatives were first identified

  黏膜相关淋巴组织淋巴瘤易位蛋白 1 (MALT1) 抑制剂的开发在肿瘤性疾病、炎症和自身免疫性疾病的治疗中具有重要价值和意义。然而，临床上缺乏有效的MALT1抑制剂。在此，首次通过高通量鉴定和设计了一类新型有效的 5-oxo-1-thioxo-4,5-dihydro-1 H - thiazolo[3,4- a ]quinazoline 抑制剂及其共价衍生物。筛选。我们证明了化合物15c、15e和20c有效抑制 MALT1 蛋白酶并对活化的 B 细胞样弥漫性大 B 细胞淋巴瘤具有低个位数微摩尔效力显示出选择性细胞毒性。此外，化合物20c以剂量依赖性方式特异性抑制 MALT1 依赖性 TMD8 细胞中的 NF-κB 信号传导并诱导细胞凋亡。更重要的是，20c在 TMD8 异种移植肿瘤模型中显示出良好的药代动力学特性和抗肿瘤功效，且无显着毒性。总的来说，这项研究为 MALT1 抑制剂的进一步结构
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090018114A1

  公开（公告）日：2009-01-15

  The present application relates to cannabinoid receptor ligands containing compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式(I)化合物的大麻素受体配体，其中A、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020042376A1

  公开（公告）日：2002-04-11

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及在治疗患有炎症性、自身免疫和神经退行性疾病的患者中使用这些组合物，用于预防缺血性损伤，并用于保存即将进行移植手术的器官。